15-Jan-2026
Illumina: Rich Valuation Amid Mounting Competitive and Execution Risks Supports Sell Rating
TipRanks (Wed, 14-Jan 5:36 AM ET)
Market Chameleon (Tue, 13-Jan 4:27 AM ET)
Illumina reports preliminary Q4 revenue of $1.15B
Seeking Alpha News (Tue, 13-Jan 9:20 AM ET)
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
PRNewswire (Tue, 13-Jan 9:15 AM ET)
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
PRNewswire (Tue, 13-Jan 9:01 AM ET)
Cathie Wood Doubles Down on High-Potential Biotech Plays
TipRanks (Tue, 13-Jan 12:42 AM ET)
PRNewswire (Mon, 12-Jan 4:08 PM ET)
Cathie Wood’s ARK Makes New Biotech Bets in Her Latest Trades — Here’s What It Sold
TipRanks (Mon, 12-Jan 8:37 AM ET)
Cathie Wood's weekly recap: tilts to advanced air mobility, sells Meta
Seeking Alpha News (Mon, 12-Jan 7:30 AM ET)
Illumina Appoints Dr. Eric Green as Chief Medical Officer
PRNewswire (Thu, 8-Jan 4:30 PM ET)
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Illumina trades on the NASDAQ stock market under the symbol ILMN.
As of January 15, 2026, ILMN stock price climbed to $145.30 with 1,595,565 million shares trading.
ILMN has a beta of 1.31, meaning it tends to be more sensitive to market movements. ILMN has a correlation of 0.22 to the broad based SPY ETF.
ILMN has a market cap of $23.02 billion. This is considered a Large Cap stock.
Last quarter Illumina reported $1 billion in Revenue and $1.34 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.18.
In the last 3 years, ILMN traded as high as $238.55 and as low as $68.70.
The top ETF exchange traded funds that ILMN belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
ILMN has underperformed the market in the last year with a return of +6.5%, while SPY returned +20.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ILMN shares. However, ILMN has outperformed the market in the last 3 month and 2 week periods, returning +59.7% and +10.8%, while SPY returned +4.8% and +1.5%, respectively. This indicates ILMN has been having a stronger performance recently.
ILMN support price is $140.39 and resistance is $147.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ILMN shares will trade within this expected range on the day.